Breakthrough male contraceptive gel shows rapid results in clinical trial
Male contraceptive gel combines hormones for faster sperm production suppression.| News-Medical
Enrollment is complete for the randomized part of ENHANCE, a large clinical trial testing a new dosing schedule for Briumvi (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (MS), […] The post ENHANCE trial testing simplified Briumvi dosing now fully enrolled appeared first on Multiple Sclerosis News Today.| Multiple Sclerosis News Today – The Web's Daily Resource for Multiple Scler...
Obexelimab, a therapy Zenas Biopharma is developing for a range of autoimmune diseases, almost completely prevented the formation of new inflammatory lesions in adults with relapsing forms of multiple sclerosis […] The post Obexelimab stops 95% of new MS brain lesions in trial appeared first on Multiple Sclerosis News Today.| Multiple Sclerosis News Today – The Web's Daily Resource for Multiple Scler...
Male contraceptive gel combines hormones for faster sperm production suppression.| News-Medical
GAINESVILLE, Fla. — Patients with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived…| ufhealth.org
One-time treatment with the gene therapy FLT201 (avigbagene parvec) may help control Gaucher disease without the need for additional therapies, according to new data from four patients in an early clinical trial. Spur Therapeutics, the company developing FLT201, presented the data at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress, held […] The post One-time gene therapy controls Gaucher disease symptoms appeared first on Gaucher Disease News.| Gaucher Disease News
Discover recent Tourette’s syndrome research, highlighting emerging therapies and biotech advances in this neurological disorder. The post Five latest advancements in Tourette’s syndrome research appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given...| Labiotech.eu
As the biotech industry in Luxembourg gradually grows, let us take a look at five biotech companies that are flourishing in the field. The post Biotech in Luxembourg: five companies that have made their name appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit ...| Labiotech.eu
The treatment drug to address insatiable hunger in people with Prader-Willi syndrome was greenlit this year. Discover five therapies in line for approval. The post Prader Willi syndrome: five much-anticipated therapies poised for approval appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, pr...| Labiotech.eu
In this week's podcast we talked with Kevin Eisenfrats, CEO of Contraline, about contraception, male contraception. The post Contraline’s ADAM in the clinic: towards a new era of male contraception? appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is give...| Labiotech.eu
The post The October 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The post Now Enrolling: STOPGAP II trial opens for patients with stomach cancer appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
Now Enrolling: EAA241 trial opens for patients with newly diagnosed multiple myeloma and kidney failure| ECOG-ACRIN Cancer Research Group
Use of CBD gel ZYN002 showed no greater effects vs. a placebo on social avoidance behavior in young people with fragile X syndrome in trial.| Fragile X News Today
The post The September 2025 <em>News from ECOG-ACRIN</em> blog is now available appeared first on ECOG-ACRIN Cancer Research Group.| ECOG-ACRIN Cancer Research Group
The first European participants in a Phase 2 trial of the Parkinson's gene therapy AB-1005 have been randomly assigned to treatment groups.| Parkinson's News Today
ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s, was found safe and well tolerated in healthy volunteers in a trial.| Parkinson's News Today
The first three Parkinson's patients who received ANPD001 saw improvements in motor symptoms and daily functioning, early trial data showed.| Parkinson's News Today
After positive trial results for TX45, Tectonic Therapeutic is planning a Phase 2 study to test its effects on blood flow in PH-ILD patients.| Pulmonary Hypertension News
Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly skin cancer.| Labiotech.eu
Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped capital.| Labiotech.eu
Treatment with esketamine, a compound related to ketamine, led to some behavioral improvements in three girls with Rett syndrome in a trial.| Rett Syndrome News
GRI-0621, an experimental oral therapy for IPF, has so far been tolerated well in an ongoing Phase 2 clinical trial.| Pulmonary Fibrosis News
GRI Bio reached an interim enrollment goal for a clinical trial testing GRI-0621, a therapy targeting natural killer T-cells to treat IPF.| Pulmonary Fibrosis News
Pending regulatory clearance in Colombia, Unravel Biosciences will launch a trial this summer testing Rett treatment RVL001 in 15 patients.| Rett Syndrome News
by Gertrud U. Rey The number of measles cases is steadily increasing across the United States, especially in areas with low vaccination rates. Instead of recommending that children be vaccinated with the measles, mumps, and rubella (MMR) vaccine, US Health and Human Services Secretary Robert F. Kennedy Jr. continues to promote ideas that are rooted …Vitamin A, Cod Liver Oil, and Measles Read More »| Virology Blog
The first four Rett syndrome patients treated with the gene therapy candidate NGN-401 have seen meaningful gains in skills, data show.| Rett Syndrome News
The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.| Fragile X News Today
Acupuncture is a form of alternative medicine that has been around for centuries, but a new study shows it could have a new use: preventing UTIs.| Scienceline
In this article, we take a look at eight biotechs that have acquired funding in recent years to fortify their GPCR-focused pipelines.| Labiotech.eu
The first patient has been dosed in a Phase 2a trial of Parkinson's therapy VTX3232, an oral medication designed to reduce inflammation.| Parkinson's News Today
The FDA has approved a Phase 2 trial to test SPG601, an oral treatment candidate, in men with fragile X syndrome.| Fragile X News Today
Treatment with telitacicept for almost six months lessened disease activity in gMG adults positive for anti-AChR antibodies, per a study.| Myasthenia Gravis News
Iaso Bio has received clearance from the FDA to start clinical trials to test its CAR T-cell therapy equecabtagene autoleucel in MS patients.| Multiple Sclerosis News Today
Uncover the promise of KRAS inhibitors in cancer treatment, as evidenced by a $200 million investment in BridgeBio's spinout.| Labiotech.eu
The first patient was dosed in the U.S. as part of a clinical trial testing of NK cell therapy candidate AlloNK for lupus nephritis.| Lupus News Today
Seattle Children's will start a clinical trial testing CAR T-cell therapy in children with lupus this summer after getting FDA clearance.| Lupus News Today
Let us take a look at how the hunt for amyotrophic lateral sclerosis (ALS) drugs has advanced over the past few years.| Labiotech.eu
Discover how GLP-1 agonists, known for treating diabetes and obesity, are now being studied for their potential in tackling heart diseases.| Labiotech.eu
